House Publications
The Debates are the report—transcribed, edited, and corrected—of what is said in the House. The Journals are the official record of the decisions and other transactions of the House. The Order Paper and Notice Paper contains the listing of all items that may be brought forward on a particular sitting day, and notices for upcoming items.
For an advanced search, use Publication Search tool.
If you have any questions or comments regarding the accessibility of this publication, please contact us at accessible@parl.gc.ca.
|
|
|
Notice PaperNo. 192 Wednesday, December 5, 2012 2:00 p.m. |
|
|
|
|
Introduction of Government Bills |
|
Introduction of Private Members' Bills |
|
Notices of Motions (Routine Proceedings) |
|
Questions |
|
| Q-10902 — December 4, 2012 — Ms. Moore (Abitibi—Témiscamingue) — With regard to Canada Economic Development: (a) what grants have been awarded in the federal riding of Abitibi–Témiscamingue in the last 10 years; (b) what projects have been funded or undertaken in the federal riding of Abitibi–Témiscamingue in the last 10 years; and (c) what were the organizations, amounts allocated and type of project? |
| Q-10912 — December 4, 2012 — Ms. Moore (Abitibi—Témiscamingue) — With regard to the various federal departments maintaining offices and services in the constituency of Abitibi–Témiscamingue, what are their detailed operating budgets, by department and service, for the years 2006 to 2012? |
| Q-10922 — December 4, 2012 — Ms. Duncan (Etobicoke North) — With regard to drug safety in Canada and the protection of Canadians’ health: (a) for each of the recommendations in the Auditor General’s 2011 fall report, Chapter 4, Regulating Pharmaceutical Drugs—Health Canada, what are the actions taken to date, and specifically, which of these actions (i) has yet to begin, (ii) is in progress, (iii) is completed; (b) for drugs produced in off-shore factories, how does Health Canada monitor safety, (i) how many inspections has it undertaken since 2006, and (ii) for each identified inspection, what was the reason for investigating, and what were the results; (c) what are all the positive and negative impacts of the “user-fee” model, by which drug companies pay to submit a drug for approval, and what, if any, research or investment has been undertaken to consider alternative models, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) if results and recommendations are available, will Health Canada be acting upon them and when; (d) will Health Canada make registering clinical trials for drugs mandatory, and if so, when; (e) what, if any, research or investment has been undertaken to examine whether the pharmaceutical industry suppresses negative clinical trial results, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) if results and recommendations are available, will Health Canada be acting upon them and when; (f) what, if any, research or investment has been given to having Health Canada provide information regarding clinical trials, including, but not limited to, information confirming safety and efficacy, the number of people in the trials, and the number of people who drop out due to bad side effects, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) if results and recommendations are available, will Health Canada be acting upon them and when; (g) what, if any, research or investment has been undertaken to identify new drugs for consumers, as in the United Kingdom, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) if results and recommendations are available, will Health Canada be acting upon them and when; (h) what, if any, research or investment has been undertaken to adopt plain language labelling, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) if results and recommendations are available, will Health Canada be acting upon them and when; (i) will Health Canada be undertaking plain language labelling and, if so, when; (j) what specific post-market monitoring of drugs does Health Canada undertake itself, (i) how many drugs have been approved since 2006, (ii) how many of these were later given safety warnings, (iii) how many of these were later removed from market, (iv) for each drug given a warning or a removal, did it follow a warning or removal by the European Medicines Agency (EMA) or the US Food and Drug Administration (FDA), (v) did Health Canada ever issue a warning or removal before the EMA/FDA; (k) what specific post-market monitoring of drugs that have had a 180-day priority review does Health Canada undertake itself, (i) how many drugs have been approved since 2006, (ii) how many were later given safety warnings, (iii) how many of these were later removed from market, (iv) for each drug given a warning or a removal, did it follow a warning or removal by the EMA or the FDA, (v) did Health Canada ever issue a warning or removal before the EMA/FDA; (l) when will Health Canada offer a list of drugs that received fast-track approval, and why fast-tracking took place, (ii) what other variables might Health Canada consider making available to increase transparency regarding priority-review drugs; (m) what, if any, research or investment has been undertaken to develop an independent drug-monitoring agency with the power to remove unsafe drugs from the market, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) if results and recommendations are available, will Health Canada be acting upon them and when; (n) what, if any, research or investment has been undertaken to provide plainly worded risk warnings, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) and if results and recommendations are available, will Health Canada be acting upon them and when; (o) will Health Canada be undertaking plainly-worded risk warnings, and if so, when; (p) how many Canadians die each year of prescription drugs in Canada, (i) what is the most recent data Health Canada has regarding these deaths, (ii) what specific action has Health Canada taken to reduce these numbers, (iii) what data does Health Canada or the Canadian Institutes for Health Research have regarding how these data are expected or predicted to change in the future; (q) what action has been taken to address each of the 59 recommendations of the coroner’s jury in the inquiry into Ms. Vanessa Young's death, what action has been taken to address each of the 16 recommendations of the coroner’s jury in the inquiry into Ms. Sara Carlin's death, and for each recommendation, (i) identify if the recommendation is being acted upon, is in progress, or is completed, (ii) if it is not being acted upon, identify why; (r) what, if any, research or investment has been undertaken to making “related to a drug prescribed” a category of death, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) if results and recommendations are available, will Health Canada be acting upon them and when; (s) what, if any, research or investment has been undertaken to determine what percentage of adverse reactions are never reported, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) if results and recommendations are available, will Health Canada be acting upon them and when; (t) what, if any, research or investment has been undertaken to make reporting adverse effects of drugs mandatory for doctors, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) and if results and recommendations are available, will Health Canada be acting upon them and when; (u) what, if any, research, or investment has been undertaken to make reporting adverse effects of drugs mandatory for pharmacists, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) if results and recommendations are available, will Health Canada be acting upon them and when; (v) what, if any, research or investment has been undertaken to make reporting adverse effects of drugs mandatory for all healthcare professionals, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) if results and recommendations are available, will Health Canada be acting upon them and when; (w) what, if any, research or investment has been undertaken to make public adverse effects reports from companies, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) if results and recommendations are available, will Health Canada be acting upon them and when; (x) what, if any, research or investment has been undertaken to make Health Canada’s on-line, adverse-reactions-to-drugs database more navigable and user-friendly, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) if results and recommendations are available, will Health Canada be acting upon them and when; (y) when will Health Canada offer a full list of every warning given for a specific drug; (z) what, if any, research or investment has been undertaken to make Health Canada’s website more user-friendly and transparent, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) and if results and recommendations are available, will Health Canada be acting upon them and when; and (aa) what, if any, research or investment has been undertaken to give Health Canada the authority to unilaterally revise a label or remove a drug from market, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) if results and recommendations are available, will Health Canada be acting upon them and when? |
| Q-10932 — December 4, 2012 — Ms. Boivin (Gatineau) — With regard to demographic information about judicial appointments for each of the last 10 years, what is the: (a) total number of judicial appointments made, by year; (b) total number of judicial appointments for each year by (i) court, (ii) province; (c) total number of judicial appointments of women, and number by year; (d) number of judicial appointments of women by (i) court, (ii) province; (e) total number of judicial appointments of visible minorities, and number by year; (f) number of judicial appointments of visible minorities by (i) court, (ii) province; (g) total number of judicial appointments of First Nations, Inuit or Metis, and number by year; (h) number of judicial appointments of First Nations, Inuit or Metis by (i) court, (ii) province; (i) number of applications made by visible minorities by (i) court, (ii) province; (j) number of applications made by women by (i) court, (ii) province? |
| Q-10942 — December 4, 2012 — Ms. Charlton (Hamilton Mountain) — With regard to Employment Insurance (EI), for each of the past seven fiscal years as well as the year-to-date: (a) what was Service Canada's overall budget for EI; (b) what was Service Canada's budget for processing EI applications; (c) what was Service Canada's budget for EI call centres; (d) what was Service Canada's budget for reviewing EI appeals before they reached a hearing; (e) what was Service Canada's budget for investigating fraud; (f) how many staff did Service Canada allocate to EI overall; (g) how many staff did Service Canada allocate to processing EI applications; (h) how many staff did Service Canada allocate to EI call centres; (i) how many staff did Service Canada allocate to reviewing EI appeals before they reached a hearing; (j) how many staff did Service Canada allocate to investigating fraud; and (k) how many members of the Board of Referees were there, broken down by region and position? |
| Q-10952 — December 4, 2012 — Ms. Charlton (Hamilton Mountain) — With regard to the Review of the Temporary Foreign Worker Program (TFWP) that was announced in November 2012: (a) which department is the lead for the review and which departments are involved; (b) what are the Terms of Reference for the Review; (c) what is the scope of the Review; (d) who is the lead conducting the Review, including, (i) their name, (ii) their position and department or organization, (iii) their duties in relation to the Terms of Reference for the Review, (iv) any other responsibilities or duties they may have with respect to the Review; (e) how was it determined which department would be the lead in the Review; (f) when did the Review begin; (g) what are the titles of any reports or studies being used to conduct the Review and who are the authors; (h) for any consultations that are part of the Review, what third party groups and stakeholders are being consulted as part of the Review, broken down by employers and employer groups representatives, labour unions and employee representative groups, non-profit groups, provinces and territories, and other groups; (i) when and how will consultations happen; (j) when are the results of the Review expected; (k) will the results of the Review be made publically available and, if so, when and how; (l) what are the findings of the Review to date; (m) with respect to the cost of the Review, (i) what is the cost of the Review, (ii) which departments are allocating resources toward the Review, (iii) what is each department allocating to the Review, including staff resources; (n) what concerns were identified within Human Resources and Skills Development Canada (HRSDC) and Citizenship and Immigration (CIC) that led to the Review; (o) when did HRSDC first become aware of the concerns that led to the Review; (p) when did CIC first become aware of the concerns that led to the Review; (q) what specific concerns does HRSDC have about HD Mining Ltd following the rules under the TFWP and when did CIC first become aware of these concerns; (r) what specific concerns does CIC have about HD Mining Ltd following the rules under the TFWP and when did CIC first become aware of these concerns; (s) what communications has HRSDC or CIC had with the Government of British Columbia with respect to any concerns about HD Mining Ltd following the rules under the TFWP; (t) with respect to the Labour Market Opinions (LMOs) that are subject to the Review, (i) how many LMOs will be subject to the Review and for which employers, (ii) what will the Review of each of those LMOs entail, (iii) what impact will the Review have on the status of these LMOs during the Review, (iv) what are the possible impacts of the Review on the status of these LMOs once the review is complete; and (u) for the CIC work permits that are subject to the Review, (i) how many work permits will be subject to the Review and for which employers, (ii) what will the review of each of those work permits entail, (iii) what impact will the Review have on the status of these work permits during the Review, (iv) what are the possible impacts of the Review on the status of these work permits once the review is complete? |
| Q-10962 — December 4, 2012 — Mr. Scarpaleggia (Lac-Saint-Louis) — With regard to federal research relating to water: (a) in which federally-owned facilities and departments, including the Experimental Lakes Area, is the government conducting research on water issues, including but not limited to research relating to fisheries, fish habitat, climate change, groundwater, water quality, and wastewater technology and processes; and (b) since January 1, 2006 what major water-related research projects have been or are currently being undertaken in these facilities and departments, ranked by project budget size? |
Notices of Motions for the Production of Papers |
|
Business of Supply |
|
| Supplementary Estimates (B) |
| UNOPPOSED VOTES |
| December 3, 2012 — The President of the Treasury Board — That the Supplementary Estimates (B) for the fiscal year ending March 31, 2013, be concurred in. |
| Voting — not later than 15 minutes before the expiry of the time provided for Government Orders, pursuant to Standing Order 81(17). |
Government Business |
|
Private Members' Notices of Motions |
|
| M-417 — December 4, 2012 — Mr. Rafferty (Thunder Bay—Rainy River) — That, in the opinion of the House, the government should establish a Royal Canadian Legion Infrastructure Renewal Fund to assist individual branches and their infrastructure renewal efforts by matching their investment in infrastructure projects at their respective branches to ensure all branches throughout Canada will continue to provide a high level of service to veterans, active personnel, their families, and the public moving forward. |
Private Members' Business |
| M-387 — October 31, 2012 — Resuming consideration of the motion of Mr. Moore (Fundy Royal), seconded by Mr. Weston (Saint John), — That, in the opinion of the House, the government should further the success of its 2006 Blue Sky Policy, which has resulted in great progress in increasing the freedom of movement of people and goods, and should: (a) seek additional opportunities to create jobs in various sectors of the economy and enhance trade and tourism; (b) work with important stakeholders to support the Blue Sky Policy; (c) recognize that increased competition benefits Canadian consumers; and (d) seek more air service agreements to serve Canada's consumer, commerce, trade and investment interests. |
| Debate — 1 hour remaining, pursuant to Standing Order 93(1). |
| Voting — at the expiry of the time provided for debate, pursuant to Standing Order 93(1). |
|
|
|
| 2 Response requested within 45 days |
|